Genetic landscape and clinical outcomes of patients with WT1-mutated myeloid neoplasms undergoing alloSCT. (A) Oncoplot depicting comutations associated with WT1. Thirteen of 33 patients had mhWT1. (B) Lollipop plot showing position of mutations among 33 patients. Two hot spots were observed: codons 301-303 and codons 312-314. (C) Variant allele frequency (VAF) of top 10 mutated genes. (D) Post-alloSCT non-relapse mortality (NRM) and RI of the entire cohort. (E) Post-alloSCT NRM and RI stratified by single or mhWT1 mutations. (F) Multivariate competing risk regression analysis for relapse among patients undergoing alloSCT. (G) Cumulative incidence of NRM and relapse stratified by WT1 mutations and associated clonal architecture. (H) DFS after alloSCT, stratified by mhWT1. (I) Multivariate Cox proportional hazard analysis for 3-year DFS after transplantation in patients with mWT1 AML. (J) Multivariate Cox proportional hazard analysis for 3-year OS after transplantation. ∗None of the patients had a very high DRI.